Dr. Cheepsattayakorn graduated Doctor of Medicine from Chiang Mai Medical School, Chiang Mai University, Chiang Mai, Thailand in 1986. He then further had trained in Internal Medicine, Pulmonology, and Radiology at Chiang Mai University Medical School. Recently, on October 26, 2019, he was bestowed the Gold Medal Award (First-Class Award) from the Chiang Mai University Medical School Alumni Association in Chiang Mai, Thailand for his academic and medical practice excellence for cerebrating the 60th Anniversary of the Chiang Mai University Medical School, Chiang Mai, Thailand that was established on October 28, 1959. His name has been mentioned in more than 700 publications in Academia Premium and his published articles have been cited in more than 220 publications (times) in 5 years in GoogleScholar repository.
Nontuberculous mycobacterial infection in HIV-infected patients, Multidrug - resistant tuberculosis patterns in HIV-infected patients, Chemokine gene polymorphisms and their susceptibility to tuberculosis, Breath Tests in Respiratory and Critical Care Medicine, Tropical Infectious Diseases and Tropical Lung Diseases, Human Genetics and Infectious Diseases, Lung Cancer, COPD, Dengue Virus Infection, Silicosis and Silicosis-Associated Tuberculosis, COVID-19 Immunogenetics, COVID-19 Nanoparticle Vaccines, Occupational and Environmental Lung Diseases, Interstitial Lung Diseases, Pulmonary Cystic Fibrosis, Idiopathic Pulmonary Fibrosis, Pulmonary Sarcoidosis, Pulmonary Immunology
Gastrointestinal Microbiota Alterations in Non-Critically-Ill and Critically-Ill COVID-19 Patients
The microbiota are related to several human diseases and influence human health. Critical functions of microbiota are decomposition of indigestible proteins, carbohydrates, digestion and absorption of nutrients, host immunity induction, function, and instruction, including vitamin biosynthesis. A recent study revealed that gut microbiota (GM) were stratified by occurrence of bloodstream infection (BSI) and intensive-care-unit (ICU) admission (p < 0.05). ICU patients and those developing BSI were specifically characterized by the over-representation of Enterococcus compared to the respective counterparts (p < 0.001), whereas Clostridiales, Streptococcus, Blautia, Oscillospira, Lachnospiraceae, and other Ruminococcaceae taxa were related to non-ICU-admitted-COVID-19 and non-BSI patients (p < 0.001).
Interestingly, Enterococcus was much overrepresented in both groups of COVID-19 patients (ICU-admitted and non-ICU-admitted), particularly, closely related to ICU-admitted-COVID-19 patients (p = 0.001, Wilcoxon test), whereas non-ICU-admitted-COVID-19 patients demonstrated enriched Ruminococcus (p = 0.0003), as well as Coprococcus, Dorea, and Oscillospira (p < 0.01). Enterobacteriaceae genera, especially Klebsiella were mainly discriminated in critically non-COVID-19 patients (p < 0.03). They also found that there was a significant increase in the Enterococcus spp.-incidence rate was identified between 2017 and 2020 (p = 0.01, Poisson regression) (14.8 (95 % CI: 0.74-2.96) in 2019 and 15.2 (95 % CI: 0.79-2.92) in 2018), whereas the relative risk of ICU-acquired E-BSI during the first 4 months of 2020 was 1.84/3.14-fold higher than in 2019. Another recent study on gut microbiota with COVID-19 severity demonstrated that gut bacteria have positive correlation with COVID-19 severity, such as Erysipelotrichia, Coprobacillus, Actinomycetaceae, Proteobacteria, Bacteroidetes, Rikenellaceae, Alistipes, etc. (p = 0.003-0.029; Correlation coefficient (Rho) = 0.81-0.92).
In conclusion, a novel concept and targeted approach of the gut- microbiota modulation due to prolonged gut microbiome dysbiosis in COVID-19 patients may be a COVID-19 and its-comorbidity therapeutic.